Evidence map›Paper›PMID 30798020›Full record

ReviewCurrent opinion in psychology2019

Methods to reduce the incidence of false negative trial results in substance use treatment research.

Rachel L Tomko, Erin A McClure, Lindsay M Squeglia, Hayley Treloar Padovano, Aimee L McRae-Clark, Nathaniel L Baker, Matthew J Carpenter, Kevin M Gray

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in psychology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Alcohol and Cannabis Use and the Developing Brain.Alcohol research : current reviews · 2021
    Review
  5. Remote Methods for Conducting Tobacco-Focused Clinical Trials.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rachel L TomkoDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States. Electronic address: tomko@musc.edu.
Erin A McClureDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States.
Lindsay M SquegliaDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States.
Hayley Treloar PadovanoDepartment of Psychiatry and Human Behavior, Brown University, United States.
Aimee L McRae-ClarkDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States.
Nathaniel L BakerDepartment of Public Health Sciences, Medical University of South Carolina, United States.
Matthew J CarpenterDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States.
Kevin M GrayDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States.
Medical University of South Carolina · USJohn Brown University · US

Funding

COCA: Project 4. Neurocircuit Strategy to Decrease Cocaine Cue ReactivityP50DA046373 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HANLON, COLLEEN A · 2019 to 2023
$9.9M
Interdisciplinary Women's Health Research at MUSCK12HD055885 · NICHD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MCGINTY, JACQUELINE F. · 2007 to 2021
$7.2M
A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use DisorderR01AA027399 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M, SQUEGLIA, LINDSAY · 2018 to 2022
$3.5M
A Randomized Controlled Trial of Varenicline for Adolescent Smoking CessationU01DA031779 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M · 2012 to 2016
$3.3M
N-Acetylcysteine and Contingency Management for Youth Cannabis Use DisorderR01DA042114 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M · 2017 to 2021
$3.1M
Advancing Varenicline as a Treatment for Cannabis Use DisorderUH3DA043231 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M, MCRAE-CLARK, AIMEE L · 2019 to 2021
$2.9M
Translational Neuropsychopharmacology Research of Nicotine AddictionR01DA038700 · NIDA · UNIVERSITY OF MISSOURI-COLUMBIA · PI FROELIGER, BRETT, GRAY, KEVIN M · 2015 to 2019
$2.9M
MID-CAREER AWARD IN PATIENT-ORIENTED DRUG ABUSE RESEARCHK24DA038240 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MCRAE-CLARK, AIMEE L · 2014 to 2023
$1.9M
Advancing Varenicline as a Treatment for Cannabis Use DisorderUG3DA043231 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M, MCRAE-CLARK, AIMEE L · 2016 to 2017
$1.7M
Neuroscience-informed Treatment Development for Adolescent Alcohol Use DisordersK23AA025399 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SQUEGLIA, LINDSAY · 2016 to 2020
$1.0M
Novel Approaches to Understanding How Alcohol Pathology Develops in AdolescentsK23AA024808 · NIAAA · BROWN UNIVERSITY · PI TRELOAR PADOVANO, HAYLEY · 2017 to 2021
$973k
Technological Innovations for the Remote Monitoring of Smoking in AdolescentsK01DA036739 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MCCLURE, ERIN A · 2014 to 2018
$771k
NIAAA NIH HHS K23 AA024808NIAAA NIH HHS K23 AA025399NIAAA NIH HHS R01 AA027399NICHD NIH HHS K12 HD055885NIDA NIH HHS K01 DA036739NIDA NIH HHS K24 DA038240NIDA NIH HHS P50 DA046373NIDA NIH HHS R01 DA038700NIDA NIH HHS R01 DA042114NIDA NIH HHS U01 DA031779NIDA NIH HHS UG3 DA043231NIDA NIH HHS UH3 DA043231
6 · The paper itself

Abstract

Treatment development and evaluation for substance use disorders are hindered when randomized controlled trials fail to show a treatment effect when one exists. This manuscript provides an overview of addressable methodological factors that may contribute to incorrect trial results. The collection of remote, naturalistic, real-time adherence and substance use data through ambulatory assessment methods in everyday life is presented as a partial solution. Other recommendations related to participant recruitment and selection, ensuring adequate consistency/fidelity and dose of treatment, and rigorously assessing clinical outcomes are discussed. With implementation of eligibility criteria verification, treatment adherence monitoring, and remote assessment of substance use and biomarkers, ambulatory assessment may help improve clinical trial success rates by improving precision, increasing reproducibility, and reducing the impact of methodological issues that may lead to inaccurate trial results.

Indexed as

False Negative ReactionsHealth Services ResearchRandomized Controlled Trials as TopicSubstance-Related DisordersHumansIncidenceMedication AdherencePatient SelectionReproducibility of ResultsResearch Design

Identifiers

PMID30798020
PMCPMC6661207
OpenAlexW2947943311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.